Autifony Therapeutics Receives £2.2M Grant from Technology Strategy Board

Autifony Therapeutics Limited, a London, UK-based developer of novel pharmaceutical treatments for hearing disorders, rewceived a £2.2m grant from the Technology Strategy Board (TSB).

Autifony, an Imperial Innovations Group plc (AIM: IVO)’s portfolio company, id advancing AUT00063, a Kv3 potassium channel modulator in development for a variety of hearing disorders.

The company, led by Charles H. Large, PhD (Chief Executive Officer), Giuseppe S. Alvaro, PhD (Founder and Head of Drug Discovery), and Peter Harris, BSc, MBBS (Chief Medical Officer), intends to use the funds to progress the development of its compound (AUT00063) and initiate a randomized, placebo controlled Phase IIa study in patients with tinnitus in the UK, which is in addition to a planned Phase IIa clinical trial in age related hearing loss, which is due to start later this year.



Join the discussion